September 7, 2018
When it comes to how to increase the development and utilization of biosimilars, the Food and Drug Administration is all ears. On Tuesday, the agency welcomed numerous physicians and experts to testify on competition and innovation in the biosimilars marketplace. And at least one physician identified a critical component in uptake: physician confidence.
August 30, 2018
Patient access developments didn’t stop for summer. As we head into fall, here are 10 quotes from the news items – and new materials – that kept the health policy conversation lively during summer 2018.
July 26, 2018
New research paints a troubling picture of patient access to prescription medication.
July 24, 2018
To import, or not to import? The question of whether to bring foreign, lower-priced versions of prescription drugs to the United States is back.
July 20, 2018
The Food and Drug Administration is tired of waiting. Of the 11 biosimilars approved by the agency, only three are available on the U.S. market. The therapies are poised to provide patients with additional – and potentially lower-cost – options for treating rheumatoid arthritis, Crohn’s disease, cancer and other diseases. But not unless patients can access them.
July 5, 2018
Imagine having severe eczema. Your hands, arms and feet are always red and irritated. Sometimes your skin is so dry it cracks. Other times you have weepy blisters.
June 29, 2018
Massachusetts Medicaid patients are breathing a collective sigh of relief.
June 25, 2018
Not everyone can afford the medication they need. To make drugs more accessible, manufacturers sometimes provide co-pay coupons to help patients cover their out-of-pocket pharmacy expenses.
June 6, 2018
First one drug manufacturer, then another, has reported that net prices for their medications dropped last year. And that’s good news for patients, right? Well, it all depends.
June 1, 2018
As the global cancer community convenes for the annual meeting of the American Society of Clinical Oncology, one question looms large: What will President Donald Trump’s blueprint to lower drug prices mean for patient access? Especially for cancer patients, who may take several medications or live on a fixed income?
